Artboard 1

OpenBiome Webinar

On December 14, 2022, the OpenBiome team held a live webinar to discuss a new FDA guidance governing the use of investigational FMT and approval of REBYOTA™.  Key takeaways and an FAQ are shared below.

A laboratory technician removes a tray of bottles containing FMT capsules from a freezer.

Key Takeaways

  • An icon of a clinician with a stool sample

    The U.S. FDA recently announced final guidance for the use of investigational FMT in the treatment of recurrent C. difficile infection (rCDI) not responsive to standard therapies.

  • StoolDonorRecruitmentScreening

    The U.S. FDA approved the first fecal microbiota product for the treatment of rCDI in adults marking a major milestone for the field and a huge win for patients.

  • FMTtreatment_Hero

    OpenBiome will continue distributing investigational FMT for patients suffering from rCDI not responsive to standard therapies.  

Frequently Asked Questions

Scroll To Top